Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

(2012) Y.-T. Tai et al.   BLOOD

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

(2012) K Giannopoulos et al.   BRITISH JOURNAL OF CANCER

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

(2012) Kimberly Noonan et al.   CLINICAL CANCER RESEARCH

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional modulation of AMP-activated protein kinase by cereblon

(2011) Kwang Min Lee et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

(2011) S. Madan et al.   BLOOD

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome

(2011) M. S. Kumar et al.   BLOOD

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome

(2011) J. Cortés-Hernández et al.   BRITISH JOURNAL OF DERMATOLOGY

Teratogenic effects of thalidomide: molecular mechanisms

(2011) Takumi Ito et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

(2011) Antonio Palumbo et al.   Expert Opinion On Drug Safety

Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos

(2011) Jinping Cheng et al.   International Journal of Nanomedicine

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study

(2011) Harry J.M. Groen et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

(2011) María Teresa Cibeira et al.   LEUKEMIA RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

(2010) S. Dutt et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

(2010) K. Noonan et al.   BLOOD

Lenalidomide down regulates the production of interferon-γ and the expression of inhibitory cytotoxic receptors of human Natural Killer cells

(2010) Nicolas Dauguet et al.   CELLULAR IMMUNOLOGY

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells

(2010) Yijiang Shi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

(2009) R. Pal et al.   BLOOD

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma

(2009) V. Racanelli et al.   BLOOD

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Cereblon is expressed in the retina and binds to voltage-gated chloride channels

(2009) Bettina Hohberger et al.   FEBS LETTERS

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

(2009) M. Jadersten et al.   HAEMATOLOGICA

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells

(2009) Mónica Bernal et al.   HUMAN IMMUNOLOGY

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

(2009) Vinay Chaudhry et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome

(2009) Jillian L Barlow et al.   NATURE MEDICINE

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

(2009) C. Therapontos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

(2008) D. C. Johnson et al.   BLOOD

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SOCS regulation of the JAK/STAT signalling pathway

(2008) Ben A. Croker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY